Vertex Pharmaceuticals Incorporated recently announced in a press release new data on its long-term PROGRESS study testing the investigational regimen ORKAMBI (lumacaftor/ivacaftor) for cystic fibrosis (CF). The data was presented at the 38th European Cystic Fibrosis Society (ECFS) Conference, June 10-13, 2015 held in Brussels, Belgium in…
News
New research is shedding light on a possible link between endometriosis in females who have cystic fibrosis. Cystic fibrosis (CF) is a genetic disorder caused by mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene that mostly affects the lungs, but also the pancreas, liver, kidneys and intestine. The…
Internationally recognized Cystic Fibrosis expert and State University of New York at Buffalo clinical professor of pediatrics Drucy S. Borowitz, MD has received the 2015 Stockton Kimball Award for outstanding scientific achievement and service She accepted the honor at a May 28 SUNY Buffalo School of Medicine and…
The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics for treating inflammatory disease through regulation of immune cell migration and activation — is CTX-4430, described as a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor that shows promise as…
Vertex Pharmaceuticals Incorporated and Parion Sciences recently announced a joint collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary conditions. Based on the agreement rights, Vertex will develop and commercialize Parion’s ENaC inhibitors, named P-1037 and P-1055, for…
The U.K. based Cystic Fibrosis Trust, a national charity that funds research into the disease and provides information and support for patients and families, has announced that the nonprofit organization will standardize using DocuSign for Digital Transaction Management in order to eliminate printing, faxing, scanning and overnighting documents in…
The selection of articles I chose for this week is an attempt to capture recent events, along with one older article, showcasing the range of articles relating to the science and increased awareness being brought to the CF community ‘Salty Girls’ photo Series Challenges Notions of Beauty and Cystic Fibrosis…
Celtaxsys has announced that the company’s phase 2 clinical trial to evaluate CTX-4430, its investigational treatment for cystic fibrosis (CF), will be supported by a $5 million grant from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis…
Corbus Pharmaceuticals Holdings, Inc., a company focused on the development and commercialization of new therapies for rare, chronic, serious inflammatory and fibrotic diseases, recently announced that its President and Chief Scientific Officer Dr. Mark A. Tepper is presenting a poster (June 1-2) at the 2015 Cystic Fibrosis Foundation Research…
The Best Late Stage Product Development Company Award was recently granted to Parion Sciences by the Triangle Business Journal and accounting firm BDO. The company, which is focused on creating novel therapies for both pulmonary and ocular medical conditions, was presented with the award at an event in Cary, North Carolina, and is part of the third-annual…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.